A U.S. alcohol maker’s $191 million investment in a Canadian marijuana firm has raised the stakes for American banks trying to navigate the risk and uncertainty tied to marijuana.
Constellation Brands, based in Victor, N.Y., is the producer of Corona beer and Robert Mondavi wine. Under a deal announced last month, the company agreed to acquire 9.9% of Canopy Growth Corp., an Ontario-based marijuana firm with a $2.8 billion market capitalization.
Several of the largest U.S. banks have relationships with Constellation Brands. Now that Constellation has invested heavily in the pot business, those banks face the question of whether to sever their relationship. If they do cut ties, they stand to lose a substantial source of revenue. But if they stay the course, they face potential legal and regulatory risks.
Until quite recently, pot companies in both the U.S. and elsewhere were typically small, privately held operations. But that is changing fast. Canopy Growth Corp. trades on the Toronto Stock Exchange under the ticker symbol WEED.
The use of marijuana for medical purposes is currently legal throughout Canada, and recreational pot is set to be legalized next year.
Because marijuana remains illegal under federal law in the U.S., the vast majority of this country’s banks either refuse to do business with the nascent industry or maintain a low profile about any involvement they have. Big banks have been particularly cautious regarding the pot industry.
It is unclear whether Constellation Brands’ recent foray into the pot business has caused any banks to reconsider their relationship with the company.
In July, the alcohol maker disclosed that it had $348 million in outstanding revolving credit loans with numerous big banks, including Bank of America, Wells Fargo, Fifth Third Bancorp, Bank of the West, SunTrust Bank, JPMorgan Chase and Goldman Sachs.
There are two reasons U.S. banks might consider cutting ties with anyone involved in the Canadian marijuana business.
The first reason is that some banks have internal policies not to do business with marijuana companies. Unless those policies explicitly apply only in countries where cannabis is illegal, these banks could run the risk of violating their own policies.
A Wells Fargo spokeswoman said that the San Francisco company’s policy not to bank marijuana business applies globally.
The other banks would not comment on their relationship with Constellation or its foray into the marijuana business. A spokesman for Constellation Brands did not respond to messages seeking comment.
The second reason banks might consider cutting ties with Constellation Brands is because of their potential legal and regulatory exposure. Even though marijuana is on its way to full legalization in Canada, it is far from clear if banks would be off the hook if they continued doing business with companies in the Canadian cannabis industry.
Douglas Fischer, chief legal officer at the National Association of Cannabis Businesses, said that the money laundering risk for U.S. banks appears to be quite low, given that Canopy Growth Corp. operates outside of the United States.
“The money isn’t dirty, for lack of a better word, because it’s not coming from violating U.S. law,” he said.
But Rusty Payne, a spokesman for the U.S. Drug Enforcement Agency, said that U.S. investments in Canadian marijuana businesses are violations of the Controlled Substances Act.
“You’re dealing in drug trafficking. You’re dealing in money laundering,” Payne said, though he also acknowledged that the DEA has limited investigative resources and has to prioritize cases.
U.S. banking regulators have not given their blessing to the Canadian pot industry, either.
Spokespeople for the Federal Deposit Insurance Corp. and the Office of the Comptroller of the Currency said that they expect depositories to follow guidance on marijuana banking that was issued by the Financial Crimes Enforcement Network in 2014.
That guidance has reassured some banks that they can manage the risk associated with state-legal cannabis businesses. But the guidance does not address the topic of foreign marijuana firms.
Robert McVay, a marijuana industry lawyer in Seattle, said in a recent blog post that prosecutors would face an uphill climb if they brought charges against a U.S. resident who invested in a legal marijuana business abroad.
But he also wrote, “Most U.S. banks will still shy away from offering any services connected with marijuana businesses even in countries that have legalized completely.”
Then again, the alcohol company’s investment in Canadian pot may prompt banks that currently take a strict no-marijuana stance to consider refining those policies.
Dante Tosetti, a former examiner at the Federal Reserve Bank of San Francisco, said that policies against cannabis are becoming harder for banks to maintain as the pot industry grows both in the U.S. and overseas.
“How are they going to be able to enforce it?” asked Tosetti, who is currently a consultant to banks.
Steve Kemmerling, the CEO of MRB Monitor, which provides data about cannabis businesses to banks, said that any banks that lend to Constellation Brands and has a no-marijuana policy should either end the relationship or revise its cannabis policy.
“If banks choose to maintain their commitments to the credit agreement by loosening their marijuana-related policy for this situation, it could be a good sign for the marijuana industry as a whole,” he said.